SCHEMBL571125

SCHEMBL571125

CCOC(=O)c1cc2cc(/C=C/C(=O)c3ccccc3)cc(C(C)CC)c2oc1=O

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAOB P27338 6/20 0.47
MAOA P21397 3/20 0.47
KDM4E B2RXH2 4/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPT P10636 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
KMT2A Q03164 1/20 0.42
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
ALDH1A1 P00352 2/20 0.40
GLA P06280 1/20 0.40
GAA P10253 1/20 0.40
MIF P14174 2/20 0.40
PFKFB3 Q16875 1/20 0.40
PGR P06401 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL570807 1.00 MAOB (0.47) MAOBMAOAKDM4EHSD17B10MAPT
SCHEMBL15166677 0.93 MAOB (0.44) MAOBMAOAKDM4EHSD17B10MAPT
SCHEMBL570599 0.93 MAOB (0.44) MAOBMAOAKDM4EHSD17B10MAPT
SCHEMBL571213 0.92 ALDH1A1 (0.42) MAOBMAOAKDM4EMAPTNPC1
SCHEMBL15166647 0.92 ALDH1A1 (0.42) MAOBMAOAKDM4EMAPTNPC1
SCHEMBL15166641 0.91 MAOB (0.48) MAOBMAOAKDM4EHSD17B10MAPT
SCHEMBL571209 0.91 MAOB (0.48) MAOBMAOAKDM4EHSD17B10MAPT
SCHEMBL15186821 0.86 MAPT (0.45) MAOBMAOAKDM4EMAPTALDH1A1
SCHEMBL15166658 0.84 GPR35 (0.41) MAOBMAOAMAPTRAB9AALDH1A1
SCHEMBL571130 0.84 GPR35 (0.41) MAOBMAOAMAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815940-B2 Coumarin-chalcones as anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-08-26 US claimed
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 US claimed
US-8815940-B2 Coumarin-chalcones as anticancer agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-08-26 US disclosed
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2013-08-15 US disclosed
EP-2601183-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS Council Of Scientific & Industrial Research (IN) 2013-06-12 EP disclosed
WO-2012017454-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2012-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130210909-A1 COUMARIN-CHALCONES AS ANTICANCER AGENTS HCCS, XPO5, CIAPIN1 MAOB 4231/4885MAOA 4442/4885KDM4E 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.